COVID-19 Hepatobiliary-pancreatic disease
Conditions
Interventions
None listed
Sponsors
Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Control group: COVID-19 patients without underlying diseases such as liver disease, cirrhosis, liver cancer, biliary-pancreatic disease, bile duct cancer, and pancreatic cancer (2) Hepatobiliary-pancreatic disease group: COVID-19 patients with liver disease, cirrhosis, liver cancer, biliary-pancreatic disease, cholangiocarcinoma, pancreatic cancer
Exclusion criteria
Exclusion criteria: The following cases willn be excluded from both the control group and the hepatobiliary-pancreatic disease group (1) If the patient requests that they do not wish to cooperate to this study (2) HIV patients (3) Patients with severe other organ failure (4) Patients with advanced cancer of other organs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mortality rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Rate of patients with severe pneumonia (Requirements of oxygen-support, invasive mechanical ventilation, hospitalization, entering intensive care unit) 2. Time to SARS-CoV-2 RT-PCR negativity 3. Duration of hospitalization | — |
Countries
Japan
Contacts
Public ContactNobuhito Taniki
Keio University School of Medicine Division of Gastroenterology and Hepatology, Department of Internal Medicine
Outcome results
None listed